SCHEMBL5715059

SCHEMBL5715059

Cc1ccc(N2CCN(C(=O)Oc3ccc(CCN4C(=O)CC(C)(C)CC4=O)cn3)CC2)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.40
HTR1A P08908 2/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
HTR7 P34969 1/20 0.40
DRD3 P35462 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
TACR3 P29371 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
ME2 P23368 5/20 0.38
ME1 P48163 5/20 0.38
ME3 Q16798 5/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714458 0.91 PANK3 (0.44) AOC3HTR1ADRD2DRD1DRD4
SCHEMBL5714605 0.90 AOC3 (0.42) AOC3HTR1AHRH3SMN1; SMN2HPGD
SCHEMBL5714563 0.90 ME2 (0.43) AOC3HTR1ADRD2DRD4HTR2A
SCHEMBL5715118 0.90 ME2 (0.43) AOC3HTR1ADRD2DRD1DRD4
SCHEMBL5715436 0.90 HRH3 (0.41) AOC3HTR1AHRH3SMN1; SMN2HPGD
SCHEMBL5714782 0.88 SMN1; SMN2 (0.53) HRH3TACR3SMN1; SMN2HPGDKDM4E
SCHEMBL5715599 0.88 ALDH1A1 (0.45) HTR1ADRD2HTR2AHTR2CHTR7
SCHEMBL5714952 0.86 HRH3 (0.36) HTR1ADRD2HTR2AHRH3
SCHEMBL5715321 0.86 HTR1A (0.39) AOC3HTR1ADRD2HTR2AHTR2C
SCHEMBL5714391 0.85 HTR1A (0.38) HTR1ADRD2DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC AOC3 2256/4885HTR1A 1889/4885DRD2 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.